Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, September 02, 2014
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

Antigen Determination in Autoimmune Hepatitis Type1
Naveen L Gupta, S Nayak, S Shakeyavar

Objectives of this project were to exploit the database in indian setting to determine nuclear antigens as target for antinuclear antibodies (ANA) in patients of autoimmune hapatitis (AIH) type1.

More information
Biopharmaceuticals Hiding in the Woods
Prof. Rodney Savidge

Suggestions are provided of how efficient industrial bioprocessing can be accomplished, independently of highly expensive molecular biology approaches, in order to recover natural products of medicinal value from wild plant species.

More information
A Mix-and-Read Cell-Based Assay for Antibody Screening Against Epidermal Growth Factor Receptor
Wayne Bowen, David Onley, Tristan Cope

The conventional antibody screening assay based on antibody-antigen binding has been enzyme-linked immunosorbent assay (ELISA). While tedious and consuming, ELISA has proved sufficient for the identification of antibodies directed against secreted antigens. However, cell surface antigens (e.g. GPCRs) provide challenges for ELISA due to the shortage of soluble antigens and high variability resulting from loss of cells during wash procedures.

More information
Facing the challenges in bio-pharmaceutical production: newly developed polymer-based ion exchange chromatography media and their application to the purification for Immunoglobulin – from egg yolk
Masakatsu Omote, Noriko Shoji, Naohiro Kuriyama and Daniel Kune

Much attention has been given to ion exchange (IEX) media as a means to improve productivity as a result of increasing demand for higher efficiency on the downstream process. Until recently, strain optimisation for high productivity and upstream purification were the bottlenecks for most bio-processes.

More information
Development and NDA-Level Validation of a Real-Time PCR Procedure for Detection and Quantification of Residual E.coli DNA Contamination of Biopharmaceutical Products
Dan Papa, Pedro J. Morales and Michael D. Sadick

Escherichia coli (E. coli) has been commonly used for the production of biopharmaceuticals. Among the impurities that must be monitored in biopharmaceuticals is residual host-cell DNA (HCD). This study describes the development and subsequent NDA-level validation of a real time PCR procedure developed in response to a client’s need to improve the sensitivity of detection and quantification of residual E. coli HCD in their drug product.

More information
Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV) antibodies detected by peptide microarrays
ahmed Abd El Wahed1, Ulrike Beutling2, Ronald Frank2, Gerhard Hunsmann1, and Hans-Joachim Fritz3

HBV and HIVenv chips with overlapping oligopeptides encompassing the full amino acid sequences of HBV and HIV polypeptides were produced. In addition, a chip displaying a library of random 4608 different 15-mers peptides (4608-RPL) was prepared. Both chips were used for analyzing monoclonal antibodies and sera from HIV- and HBV-infected individuals. 4608-RPL could be used for identifying target sequences of antibodies without prior knowledge of the corresponding immunizing antigen.

More information
Transfecting Small Molecules, Peptides
Van Q., Atze K., Litzenberger D., Ackerstaff J.T., Strübing Y., Yolcu D., Franke S.,Mobbs K.J. and Kazinski M.

The Nucleofector® Technology enables efficient and reproducible transfection of primary cells and cell lines at throughputs of up to 96 samples per run. Nucleofection® now extends its range of application to deliver small molecules substrates and protein substrates such as peptides, proteins and antibodyconjugates.

More information
<< 1 2 >>
Showing Results 11 - 17 of 17
Scientific News
Understanding and Improving the Body's Fight Against Pathogens
A*STAR scientists find new targets for modulating antibody response.
NIH to Launch Human Safety Study of Ebola Vaccine Candidate
Trial is First in Series of Accelerated Safety Studies of Ebola Vaccines.
MU Researchers Discover Protein's Ability To Inhibit HIV Release
TIM-family proteins have the ability to block the release of HIV and other viruses.
High Capacity Antibody Purification
Researchers from the A*Star Bioprocessing Technology Institute have used magnetic nanoparticles to break the capacity barrier for antibody purification.
Experimental Chikungunya Vaccine Induces Robust Antibody Response
Vaccine developed by NIH scientists performs well in early clinical trial.
The Future of Targeted Therapy in Rheumatology: Biologics or Small Molecules?
While biologics can modulate extracellular protein-protein interactions, intracellular processes can be more effectively targeted by small molecules.
Injected Vaccine Could Help Eradicate Polio
Re-introducing a type of polio vaccine that fell out of favour in the 1960s could hasten eradication of the disease.
Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
A Key Step Toward a Safer Strep Vaccine
Gene discovery identifies molecular pathway to potential preventive treatment.
Separation of mAbs Molecular Variants by Analytical HIC-HPLC
HIC-HPLC is a less widely used analytical technique compared with standard methods for separating variants based on size, charge or electrophoretic mobility.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv